Myriad's impact on gene patents

In the three years since the United States Supreme Courts decision in AMP v. Myriad, there has been much debate and speculation about the impact of the case on the biotech industry, particularly on the status of gene patents. The nuance of the decision left open many questions and was far from illum...

Full description

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 34; no. 11; pp. 1119 - 1123
Main Authors Aboy, Mateo, Liddell, Kathleen, Liddicoat, Johnathon, Crespo, Cristina
Format Journal Article
LanguageEnglish
Published United States Nature Publishing Group 01.11.2016
Subjects
Algorithms
Biotechnology industry
Drug Industry - legislation & jurisprudence
Genes
Genetic research
Intellectual property
Management
Patent law
Patent licensing
Patents as Topic
Supreme Court Decisions
United States
United States
Online AccessGet full text

Cover

More Information
Summary:In the three years since the United States Supreme Courts decision in AMP v. Myriad, there has been much debate and speculation about the impact of the case on the biotech industry, particularly on the status of gene patents. The nuance of the decision left open many questions and was far from illuminating.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.3719